Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 1.80B |
| Revenue (ttm) | 74.68M |
| Net Income (ttm) | -644.76M |
| Shares Out | 528.20M |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,844,840 |
| Open | 3.430 |
| Previous Close | 3.480 |
| Day's Range | 3.380 - 3.495 |
| 52-Week Range | 2.800 - 7.180 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 7.50 (+119.62%) |
| Earnings Date | May 5, 2026 |
About RXRX
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ... [Read more]
Financial Performance
In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 119.62% from the latest price.
News
Recursion Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transitioned to a data-driven, diversified model post-merger, emphasizing regular clinical and partnership milestones. Major partnerships with Sanofi and Roche are progressing, with multiple clinical programs advancing and a strong focus on financial discipline and platform evolution.
Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in ...
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Citeline, a leader in clinical solutions for the life sciences, announced an expanded strategic partnership with Recursion, a leading tech-bio company.
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodma...
Recursion Pharmaceuticals Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
A unified AI-driven drug discovery platform has emerged from a recent merger, integrating chemistry, biology, and real-world data to optimize clinical development. The company has streamlined its pipeline, secured major partnerships, and achieved significant milestones, with multiple clinical readouts and operational efficiencies expected to drive near-term value.
Recursion Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The discussion highlighted a disciplined, data-driven approach to portfolio management, significant operational efficiencies, and a strong focus on value realization from partnerships. Proprietary data assets, targeted platform investment, and a mission-driven culture underpin competitive differentiation and financial sustainability.
Recursion Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The platform has evolved into an integrated, data-driven system with strong pharma and tech partnerships, enabling risk-diversified drug discovery and accelerated clinical progress. Financial discipline and strict go/no-go criteria guide pipeline advancement, with major data updates expected in 2024 and 2027.
Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025
First AI-enabled clinical proof of concept achieved in FAP, with strong progress across a diversified pipeline and $500M+ in partnership inflows. Operating expenses reduced 35% year-over-year, extending cash runway to early 2028.
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and fin...
Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC
Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in...
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.
Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion Pharmaceuticals and autonomous-driving company WeRide.
Recursion Pharmaceuticals Transcript: 28th Annual Needham Growth Conference Virtual
AI-driven platform integrates proprietary data and automation, supporting both internal drug development and lucrative partnerships. Recent leadership transition brought operational discipline and cost efficiency. Lead asset REC-4881 showed strong clinical results, with a robust pipeline and financial runway through 2027.
Recursion Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted momentum in AI-driven drug discovery, with clinical proof of concept achieved in a high-need disease and a robust pipeline supported by strong partnerships and disciplined operations. Upcoming milestones include FDA engagement, new data readouts, and further platform innovation.
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, N...
3 Small AI Plays to Buy for 2026
Wall Street is ending 2026 on a generally positive note, with the benchmark S&P 500 Index set to finish the year at a 17% return rate. All eyes are now on technology titans like Nvidia, Microsoft, Alp...
What's Happening With RXRX Stock?
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However...
Recursion Pharmaceuticals Transcript: Study Update
REC-4881, a selective MEK1/2 inhibitor identified via AI, showed rapid and durable reductions in polyp burden for FAP patients in a Phase 1/2 study, with a favorable safety profile and effects persisting 12 weeks post-treatment. Experts highlighted its potential to address a major unmet need and reduce the burden of lifelong interventions.
Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial
Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare gen...
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from ...
Jim Cramer: This Health Care Stock Has Been 'Horrendous'
On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks.
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Leadership transition brings renewed focus on AI-driven drug discovery, operational discipline, and talent. Proprietary data and end-to-end AI integration differentiate the platform, with strong progress in FAP and oncology programs. Key data updates and milestones are expected in the coming year.
Recursion Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Leadership transition is underway with a focus on continuity and operational efficiency. The company is advancing a robust pipeline in oncology and rare disease, leveraging AI-driven drug discovery and deep strategic partnerships. Strong financials support a runway through 2027, with key clinical and partnership milestones ahead.
Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025
Leadership transition and strong financial discipline position the company for sustained growth, with $785M in cash and a runway through 2027. Key milestones include a $30M Roche/Genentech payment, robust pipeline progress, and continued AI-driven innovation.